Board Appointment

Oxford BioDynamics PLC

27 August 2026

 

27 August 2026                                        

Oxford BioDynamics Plc

("OBD" or the "Company")

Board Appointment

Oxford, UK - 27 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, today announces the appointment of Richard Compton, Chief Executive Officer, to the Board as an Executive Director with immediate effect. The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad.

Iain Ross, Non-Executive Chairman of Oxford BioDynamics, said:  

"I am delighted to welcome Richard to the Board of OBD. In the short time he has been with the Company as CEO he has proven he has the qualities and experience to lead the team to commercial success. With the support of the shareholders I believe he will be able to realise the success for which we have all been striving."

The following disclosures are provided in respect of Richard Alan Compton, aged 56, pursuant to Schedule 2(g) of the AIM Rules for Companies.

Mr Compton holds 300,000,000 ordinary shares in the capital of the Company, representing 2.2% of the Company's ordinary share capital.

Current Directorships / Partnerships	Previous Directorships / Partnerships (Last 5 years)
Compton Advisory Ltd (Company No. 16851684)	None.

For further information please contact:

Oxford BioDynamics Plc Iain Ross, Non-Executive Chairman Richard Compton, CEO Paul Stockdale, CFO	[phone]
Singer Capital Markets - Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley	[phone]
OAK Securities - Joint Broker Matthew Clarke / Jerry Keen	[phone]
Camarco - Financial PR Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young	[phone] [e-mail]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.

Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed. 

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.

The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.

 

END